Conventional and proteomic technologies for the detection of early stage malignancies: Markers for ovarian cancer

Critical Reviews in Clinical Laboratory Sciences

Volumn 44, Issue 1, 2007, Pages 87-114

  Lee, Catherine J ^a   Ariztia, Edgardo V ^a   Fishman, David A ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Low molecular weight proteins; Mass spectrometry; Peptide fragments; Protein microarray; Proteomics; Serum based proteomic patterns

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; DATA ANALYSIS; HUMAN; LABORATORY TEST; LASER CAPTURE MICRODISSECTION; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS; VALIDATION STUDY;

CARCINOMA; EARLY DIAGNOSIS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 33845737437     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.1080/10408360600778885     Document Type: Review

References (124)

1. Ariztia E, Lee CJ, Gogoi R, Fishman DA. The tumor microenvironment: key to early detection. Crit Rev Clin Lab Sci 2006; 43: 393-425.
2. Ahram M, Adkins JN, Auberry DL, Wunschel DS, Springer DL. A proteomic approach to characterize protein shedding. Proteomics 2005; 5: 123-131.
3. Lowenthal MS, Mehta AI, Frogale K, Bandle RW, Araujo RP, Hood BL, Veenstra TD, Conrads TP, Goldsmith P, Fishman D, Petricoin EF, 3rd, Liotta LA. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem 2005; 51: 1933-1945.
4. Kavallaris M, Marshall GM. Proteomics and disease: opportunities and challenges. Med J Aust 2005; 182: 575-579.
5. Petricoin EF 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, Simone CB, Levine PJ, Linehan WM, Emmert-Buck MR, Steinberg SM, Kohn EC, Liotta LA. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002; 94: 1576-1578.
6. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003; 3: 267-275.
7. Petricoin EF, Liotta LA. Proteomic approaches in cancer risk and response assessment. Trends Mol Med 2004; 10: 59-64.
8. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004; 15: 24-30.
9. Plebani M. Proteomics: the next revolution in laboratory medicine? Clin Chim Acta 2005; 357: 113-122.
10. Somiari RI, Somiari S, Russell S, Shriver CD. Proteomics of breast carcinoma. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 815: 215-225.
11. Dunckley T, Coon KD, Stephan DA. Discovery and development of biomarkers of neurological disease. Drug Discov Today 2005; 10: 326-334.
12. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004; 3: 367-378.
13. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004; 3: 355-366.
14. Ozols RF, Rubin SC, Dembo Al, Robboy SJ. Epithelial ovarian cancer. In Hoskins WJ, Perez CA, Young RC, Eds., Principles and Practice of Gynecologic Oncology, 3rd Ed. Pp. 981-1058. Philadelphia, Lippincott Williams and Wilkins, 2000.
15. Zurawski VR Jr, Orjaseter H, Andersen A, Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer 1988; 42: 677-680.
16. Bast RC Jr, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, Lu K, Liu J, Fishman D, Mills G. Early detection of ovarian cancer: promise and reality. Cancer Treat Res 2002; 107: 61-97.
17. Friedlander ML. Prognostic factors in ovarian cancer. Semin Oncol 1998; 25: 305-314.
18. Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellstrom KE. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003; 63: 3695-3700.
19. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005; 65: 2162-2169.
20. Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS, Cramer DW. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001; 93: 1458-1464.
21. Mills GB, Bast RC, Jr., Srivastava S. Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. J Natl Cancer Inst 2001; 93: 1437-1439.
22. Wong KK, Cheng RS, Mok SC. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques 2001; 30: 670-675.
23. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287: 1671-1679.
24. Yousef GM, Diamandis EP. Expanded human tissue kallikrein family - a novel panel of cancer biomarkers. Tumour Biol 2002; 23: 185-192.
25. Ghosh MC, Grass L, Soosaipillai A, Sotiropoulou G, Diamandis EP. Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumour Biol 2004; 25: 193-199.
26. Hassan R, Kreitman RJ, Pastan I, Willingham MC. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 2005; 13: 243-247.
27. Stanley ER, Guilbert LJ, Tushinski RJ, Bartelmez SH. CSF-1-a mononuclear phagocyte lineagespecific hemopoietic growth factor. J Cell Biochem 1983; 21: 151-159.
28. Xu FJ, Ramakrishnan S, Daly L, Soper JT, Berchuck A, Clarke-Pearson D, Bast RC Jr. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am J Obstet Gynecol 1991; 165: 1356-1362.
29. Xu FJ, Yu YH, Li BY, Moradi M, Elg S, Lane C, Carson L, Ramakrishnan S. Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells. Cancer Res 1991; 51: 4012-4019.
30. Kumanov P, Nandipati KC, Tomova A, Robeva R, Agarwal A. Significance of inhibin in reproductive pathophysiology and current clinical applications. Reprod Biomed Online 2005; 10: 786-812.
31. Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, Casey G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998; 280: 719-723.
32. Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, Tanyi J, Tabassam FH, Wiener J, Lapushin R, Yu S, Parrott JA, Compton T, Tribley W, Fishman D, Stack MS, Gaudette D, Jaffe R, Furui T, Aoki J, Erickson JR. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res 2002; 107: 259-283.
33. Baron AT, Cora EM, Lafky JM, Boardman CH, Buenafe MC, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 103-113.
34. Negishi Y, Iwabuchi H, Sakunaga H, Sakamoto M, Okabe K, Sato H, Asano G. Serum and tissue measurements of CA72-4 in ovarian cancer patients. Gynecol Oncol 1993; 48: 148-154.
35. Terry KL, Sluss PM, Skates SJ, Mok SC, Ye B, Vitonis AF, Cramer DW. Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers 2004; 20: 53-70.
36. van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Bast RC Jr, Hacker NF. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 2001; 92: 2837-2844.
37. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004; 10: 3291-3300.
38. McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, Hellstrom I. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 2004; 95: 9-15.
39. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, Yue L, Bray-Ward P, Ward DC. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 7677-7682.
40. Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods 2000; 243: 243-255.
41. Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, Bigbee WL, Herberman RB, Lokshin AE. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 981-987.
42. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC Jr. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005; 99: 267-277.
43. Skates SJ, Horick N, Yu Y, Xu FJ, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Zhang Z, Bast RC Jr. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 2004; 22: 4059-4066.
44. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004; 22: 4700-4710.
45. Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA, Cannistra SA. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 2005; 23: 7911-7918.
46. Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, Jonas D, Libermann TA. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 2005; 11: 5730-5739.
47. Dunbar SA. Applications of Luminex(R) xMAPtrade mark technology for rapid, high-throughput multiplexed nucleic acid detection. Clin Chim Acta 2006; 363: 71-82.
48. Johann DJ Jr, McGuigan MD, Patel AR, Tomov S, Ross S, Conrads TP, Veenstra TD, Fishman DA, Whiteley GR, Petricoin EF 3rd, Liotta LA. Clinical proteomics and biomarker discovery. Ann NY Acad Sci 2004; 1022: 295-305.
49. Posadas EM, Simpkins F, Liotta LA, MacDonald C, Kohn EC. Proteomic analysis for the early detection and rational treatment of cancer-realistic hope? Ann Oncol 2005; 16: 16-22.
50. Chen R, Pan S, Brentnall TA, Aebersold R. Proteomic profiling of pancreatic cancer for biomarker discovery. Mol Cell Proteomics 2005; 4: 523-533.
51. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA, Liotta LA. Laser capture microdissection. Science 1996; 274: 998-1001.
52. Banks RE, Dunn MJ, Forbes MA, Stanley A, Pappin D, Naven T, Gough M, Harnden P, Selby PJ. The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis-preliminary findings. Electrophoresis 1999; 20: 689-700.
53. Craven RA, Totty N, Harnden P, Selby PJ, Banks RE. Laser capture microdissection and twodimensional polyacrylamide gel electrophoresis: evaluation of tissue preparation and sample limitations. Am J Pathol 2002; 160: 815-822.
54. Zhou G, Li H, DeCamp D, Chen S, Shu H, Gong Y, Flaig M, Gillespie JW, Hu N, Taylor PR, Emmert-Buck MR, Liotta LA, Petricoin EF 3rd, Zhao Y. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 2002; 1: 117-124.
55. Petricoin EF, Ornstein DK, Liotta LA. Clinical proteomics: applications for prostate cancer biomarker discovery and detection. Urol Oncol 2004; 22: 322-328.
56. Liotta LA, Petricoin EF 3rd, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC. General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer. Gynecol Oncol 2003; 88: S25-28; discussion S37-42.
57. Celis JE, Gromov P, Cabezon T, Moreira JM, Ambartsumian N, Sandelin K, Rank F, Gromova I. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics 2004; 3: 327-344.
58. Mobley JA, Lam YW, Lau KM, Pais VM, L'Esperance JO, Steadman B, Fuster LM, Blute RD, Taplin ME, Ho SM. Monitoring the serological proteome: the latest modality in prostate cancer detection. J Urol 2004; 172: 331-337.
59. Ornstein DK, Rayford W, Fusaro VA, Conrads TP, Ross SJ, Hitt BA, Wiggins WW, Veenstra TD, Liotta LA, Petricoin EF 3rd. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol 2004; 172: 1302-1305.
60. Banez LL, Srivastava S, Moul JW. Proteomics in prostate cancer. Curr Opin Urol 2005; 15: 151-156.
61. Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer. I. Assessment of platform reproducibility. Clin Chem 2005; 51: 102-112.
62. Fuller AP, Palmer-Toy D, Erlander MG, Sgroi DC. Laser capture microdissection and advanced molecular analysis of human breast cancer. J Mammary Gland Biol Neoplasia 2003; 8: 335-345.
63. Ramus C, Gonzalez de Peredo A, Dahout C, Gallagher M, Garin J. An optimized strategy for ICAT quantification of membrane proteins. Mol Cell Proteomics 2005; 5:68-78.
64. Ong SE, Foster LJ, Mann M. Mass spectrometric-based approaches in quantitative proteomics. Methods 2003; 29: 124-130.
65. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-577.
66. Grizzle WE, Adam BL, Bigbee WL, Conrads TP, Carroll C, Feng Z, Izbicka E, Jendoubi M, Johnsey D, Kagan J, Leach RJ, McCarthy DB, Semmes OJ, Srivastava S, Thompson IM, Thornquist MD, Verma M, Zhang Z, Zou Z. Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer. Dis Markers 2003; 19: 185-195.
67. Li J, White N, Zhang Z, Rosenzweig J, Mangold LA, Partin AW, Chan DW. Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population. J Urol 2004; 171: 1782-1787.
68. Loboda A, Ackloo S, Chernushevich IV. A high-performance matrix-assisted laser desorption/ ionization orthogonal time-of-flight mass spectrometer with collisional cooling. Rapid Commun Mass Spectrom 2003; 17: 2508-2516.
69. Ackloo S, Loboda AV. Applications of a matrix-assisted laser desorption/ionization orthogonal time-of-flight mass spectrometer. l Metastable decay and collision-induced dissociation for sequencing peptides. Rapid Commun Mass Spectrom 2005; 19: 1-8.
70. Goodacre R, Neal MJ, Kell DB, Greenham LW, Noble WC, Harvey RG. Rapid identification using pyrolysis mass spectrometry and artificial neural networks of Propionibacterium acnes isolated from dogs. J Appl Bacteriol 1994; 76: 124-134.
71. Holland RD, Wilkes JG, Rafii F, Sutherland JB, Persons CC, Voorhees KJ, Lay JO Jr. Rapid identification of intact whole bacteria based on spectral patterns using matrix-assisted laser desorption/ ionization with time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 1996; 10: 1227-1232.
72. Conrads TP, Fusaro VA, Ross S, Johann D, Rajapakse V, Hitt BA, Steinberg SM, Kohn EC, Fishman DA, Whitely G, Barrett JC, Liotta LA, Petricoin EF 3rd, Veenstra TD. High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer 2004; 11: 163-178.
73. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, Reddy ST, Farias-Eisner R. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003; 100: 12343-12348.
74. Rai AJ, Zhang Z, Rosenzweig J, Shih Ie M, Pham T, Fung ET, Sokoll LJ, Chan DW. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 2002; 126: 1518-1526.
75. Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, Horick NK, Licklider LJ, Schorge JO, Berkowitz RS, Mok SC. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003; 9: 2904-2911.
76. Howard BA, Wang MZ, Campa MJ, Corro C, Fitzgerald MC, Patz EF Jr. Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics 2003; 3: 1720-1724.
77. Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB, Tikhonova OV, Goufman EI, Zgoda VG, Taranets IN, Makarov OV, Archakov AI. Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 2005; 5: 3790-3797.
78. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64: 5882-5890.
79. Yu JK, Zheng S, Tang Y, Li L. An integrated approach utilizing proteomics and bioinformatics to detect ovarian cancer. J Zhejiang Univ Sci B 2005; 6: 227-231.
80. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004; 96: 353-356.
81. Adkins JN, Varnum SM, Auberry KJ, Moore RJ, Angell NH, Smith RD, Springer DL, Pounds JG. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 2002; 1: 947-955.
82. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature 2003; 425: 905.
83. Mehta AI, Ross S, Lowenthal MS, Fusaro V, Fishman DA, Petricoin EF 3rd, Liotta LA. Biomarker amplification by serum carrier protein binding. Dis Markers 2003; 19: 1-10.
84. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003; 2: 1096-1103.
85. Zhou M, Lucas DA, Chan KC, Issaq HJ, Petricoin EF 3rd, Liotta LA, Veenstra TD, Conrads TP. An investigation into the human serum "interactome." Electrophoresis 2004; 25: 1289-1298.
86. Xiao Z, Adam BL, Cazares LH, Clements MA, Davis JW, Schellhammer PF, Dalmasso EA, Wright GL Jr. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 2001; 61: 6029-6033.
87. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62: 3609-3614.
88. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, Feng Z, Semmes OJ, Wright GL Jr. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002; 48: 1835-1843.
89. Lehrer S, Roboz J, Ding H, Zhao S, Diamond EJ, Holland JF, Stone NN, Droller MJ, Stock RG. Putative protein markers in the sera of men with prostatic neoplasms. BJU Int 2003; 92: 223-225.
90. Chanin TD, Merrick DT, Franklin WA, Hirsch FR. Recent developments in biomarkers for the early detection of lung cancer: perspectives based on publications 2003 to present. Curr Opin Pulm Med 2004; 10: 242-247.
91. Granville CA, Dennis PA. An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol 2005; 32: 169-176.
92. Meyerson M, Carbone D. Genomic and proteomic profiling of lung cancers: lung cancer classifi-cation in the age of targeted therapy. J Clin Oncol 2005; 23: 3219-3226.
93. Yang SY, Xiao XY, Zhang WG, Sun XZ, Zhang LJ, Zhang W, Zhou B, Chen GA, He DC. Application of serum surface-enhanced laser desorption/ionization proteomic patterns in distinguishing lung cancer patients from healthy people. Chin Med J (Engl) 2005; 118: 1036-1039.
94. Wong YF, Cheung TH, Lo KW, Wang VW, Chan CS, Ng TB, Chung TK, Mok SC. Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix. Cancer Lett 2004; 211: 227-234.
95. Castagna A, Antonioli P, Astner H, Hamdan M, Righetti SC, Perego P, Zunino F, Righetti PG. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 2004; 4: 3246-3267.
96. Iwaki H, Kageyama S, Isono T, Wakabayashi Y, Okada Y, Yoshimura K, Terai A, Arai Y, Iwamura H, Kawakita M, Yoshiki T. Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma-synuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Sci 2004; 95: 955-961.
97. Vlahou A, Laronga C, Wilson L, Gregory B, Fournier K, McGaughey D, Perry RR, Wright GL Jr, Semmes OJ. A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 2003; 4: 203-209.
98. Luo Y, Zhang J, Liu Y, Shaw AC, Wang X, Wu S, Zeng X, Chen J, Gao Y, Zheng D. Comparative proteome analysis of breast cancer and normal breast. Mol Biotechnol 2005; 29: 233-244.
99. Alessandro R, Belluco C, Kohn EC. Proteomic approaches in colon cancer: promising tools for new cancer markers and drug target discovery. Clin Colorectal Cancer 2005; 4: 396-402.
100. Chen J, Kahne T, Rocken C, Gotze T, Yu J, Sung JJ, Chen M, Hu P, Malfertheiner P, Ebert MP. Proteome analysis of gastric cancer metastasis by two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-mass spectrometry for identification of metastasis-related proteins. J Proteome Res 2004; 3: 1009-1016.
101. He QY, Chen J, Kung HF, Yuen AP, Chiu JF. Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics. Proteomics 2004; 4: 271-278.
102. Vimalachandran D, Costello E. Proteomic technologies and their application to pancreatic cancer. Expert Rev Proteomics 2004; 1: 493-501.
103. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, Hochstrasser DF, Sanchez JC. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003; 3: 1486-1494.
104. Lewczuk P, Esselmann H, Meyer M, Wollscheid V, Neumann M, Otto M, Maler JM, Ruther E, Kornhuber J, Wiltfang J. The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. Rapid Commun Mass Spectrom 2003; 17: 1291-1296.
105. Uchida T, Fukawa A, Uchida M, Fujita K, Saito K. Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid. J Proteome Res 2002; 1: 495-499.
106. Guillaume E, Zimmermann C, Burkhard PR, Hochstrasser DF, Sanchez JC. A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2003; 3: 1495-1499.
107. Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS, Cramer DW. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 2006; 12: 432-441.
108. Liotta LA, Petricoin EF. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 2006; 116: 26-30.
109. Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA, Petricoin EF 3rd, Wulfkuhle JD. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 2005; 4: 346-355.
110. Boyce EA, Kohn EC. Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets. Int J Gynecol Cancer 2005; 15: 266-273.
111. Espina V, Mehta AI, Winters ME, Calvert V, Wulfkuhle J, Petricoin EF 3rd, Liotta LA. Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics 2003; 3: 2091-2100.
112. Liotta L, Petricoin E. Molecular profiling of human cancer. Nat Rev Genet 2000; 1: 48-56.
113. Wulfkuhle JD, McLean KC, Paweletz CP, Sgroi DC, Trock BJ, Steeg PS, Petricoin EF 3rd. New approaches to proteomic analysis of breast cancer. Proteomics 2001; 1: 1205-1215.
114. Petricoin EF 3rd, Bichsel VE, Calvert VS, Espina V, Winters M, Young L, Belluco C, Trock BJ, Lippman M, Fishman DA, Sgroi DC, Munson PJ, Esserman LJ, Liotta LA. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol 2005; 23: 3614-3621.
115. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin IE, Liotta LA. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001; 20: 1981-1989.
116. Wulfkuhle JD, Aquino JA, Calvert VS, Fishman DA, Coukos G, Liotta LA, Petricoin EF 3rd. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 2003; 3: 2085-2090.
117. Rai AJ, Stemmer PM, Zhang Z, Adam BL, Morgan WT, Caffrey RE, Podust VN, Patel M, Lim LY, Shipulina NV, Chan DW, Semmes OJ, Leung HC. Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers. Proteomics 2005; 5: 3467-3474.
118. Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res 1997; 3: 999-1007.
119. Garbis S, Lubec G, Fountoulakis M. Limitations of current proteomics technologies. J Chromatogr A 2005; 1077: 1-18.
120. Swatton JE, Prabakaran S, Karp NA, Lilley KS, Bahn S. Protein profiling of human postmortem brain using 2-dimensional fluorescence difference gel electrophoresis (2-D DIGE). Mol Psychiatry 2004; 9: 128-143.
121. Patton WF. Detection technologies in proteome analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 771: 3-31.
122. Patton WF, Schulenberg B, Steinberg TH. Two-dimensional gel electrophoresis; better than a poke in the ICAT? Curr Opin Biotechnol 2002; 13: 321-328.
123. McDonald WH, Yates JR, 3rd. Shotgun proteomics and biomarker discovery. Dis Markers 2002; 18: 99-105.
124. Washburn MP, Wolters D, Yates JR 3rd. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001; 19: 242-247.